ES2128117T3 - Antagonistas del receptor de endotelina. - Google Patents

Antagonistas del receptor de endotelina.

Info

Publication number
ES2128117T3
ES2128117T3 ES96103608T ES96103608T ES2128117T3 ES 2128117 T3 ES2128117 T3 ES 2128117T3 ES 96103608 T ES96103608 T ES 96103608T ES 96103608 T ES96103608 T ES 96103608T ES 2128117 T3 ES2128117 T3 ES 2128117T3
Authority
ES
Spain
Prior art keywords
receptor antagonists
endothelin receptor
sup
substituted
nafthyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96103608T
Other languages
English (en)
Inventor
Mathias Dr Osswald
Werner Dr Mederski
Dieter Dr Dorsch
Claudia Dr Wilm
Claus Dr Schmitges
Maria Christadler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Application granted granted Critical
Publication of ES2128117T3 publication Critical patent/ES2128117T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

COMPUESTOS DE FORMULA I DONDE -A=B-C=D- ES UN GRUPO -CH=CH-CH=CH-, EN EL QUE 1 O 2 CH PUEDEN ESTAR SUSTITUIDOS POR N, AR ES UN FENILO O NAFTILO UNSUSTITUIDO O SUSTITUIDO, R{SUP,1}, R{SUP,2}, R{SUP,3} SON, INDEPENDIENTEMENTE UNO DE OTRO, H O UN SUSTITUYENTE, X ES O O S, O SUS SALES, TIENEN PROPIEDADES ANTAGONISTAS DEL RECEPTOR DE LA ENDOTELINA.
ES96103608T 1995-03-18 1996-03-08 Antagonistas del receptor de endotelina. Expired - Lifetime ES2128117T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19509950A DE19509950A1 (de) 1995-03-18 1995-03-18 Endothelin-Rezeptor-Antagonisten

Publications (1)

Publication Number Publication Date
ES2128117T3 true ES2128117T3 (es) 1999-05-01

Family

ID=7757094

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96103608T Expired - Lifetime ES2128117T3 (es) 1995-03-18 1996-03-08 Antagonistas del receptor de endotelina.

Country Status (26)

Country Link
US (1) US5726194A (es)
EP (1) EP0733626B1 (es)
JP (1) JPH08269027A (es)
KR (1) KR100424045B1 (es)
CN (1) CN1061652C (es)
AR (1) AR002284A1 (es)
AT (1) ATE175666T1 (es)
AU (1) AU705559B2 (es)
BR (1) BR9601028A (es)
CA (1) CA2171934C (es)
CO (1) CO4700473A1 (es)
CZ (1) CZ288001B6 (es)
DE (2) DE19509950A1 (es)
DK (1) DK0733626T3 (es)
ES (1) ES2128117T3 (es)
FI (1) FI960953A (es)
GR (1) GR3029893T3 (es)
HU (1) HUP9600663A3 (es)
NO (1) NO305907B1 (es)
PL (1) PL184332B1 (es)
RU (1) RU2168503C2 (es)
SK (1) SK280926B6 (es)
TR (1) TR199600212A2 (es)
TW (1) TW363060B (es)
UA (1) UA48116C2 (es)
ZA (1) ZA962144B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6030991A (en) * 1993-05-20 2000-02-29 Texas Biotechnology Corp. Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6376523B1 (en) 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6541498B2 (en) 1993-05-20 2003-04-01 Texas Biotechnology Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6613804B2 (en) 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH09124620A (ja) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
DE19543639A1 (de) * 1995-11-23 1997-05-28 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
SG87052A1 (en) 1996-02-20 2002-03-19 Bristol Myers Squibb Co Pinacol ester intermediates useful for the preparation of biphenyl isoxazole sulfonamides
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
DE19606980A1 (de) * 1996-02-24 1997-08-28 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
DE19607096A1 (de) * 1996-02-24 1997-08-28 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
US5804585A (en) 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
DE19653037A1 (de) * 1996-12-19 1998-06-25 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
WO1998033781A1 (en) * 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
DE19710831A1 (de) * 1997-03-15 1998-09-17 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
DE19712141A1 (de) * 1997-03-22 1998-09-24 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
JP3455233B2 (ja) 1997-04-28 2003-10-14 テキサス・バイオテクノロジー・コーポレイシヨン エンドテリン介在障害治療用のスルホンアミド類
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
DE19731571A1 (de) * 1997-07-23 1999-01-28 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
JP2002540088A (ja) 1999-03-19 2002-11-26 ブリストル−マイヤーズ スクイブ カンパニー ビフェニルイソキサゾール・スルホンアミド化合物の製造法
DE10155076A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
RU2008136317A (ru) * 2006-03-13 2010-04-20 Инсайсив Фармасьютикалз, Инк. (US) Способы и композиции для лечения диагностикой сердечной недостаточности
AU2007225207A1 (en) * 2006-03-13 2007-09-20 Encysive Pharmaceuticals, Inc. Formulations of sitaxsentan sodium
US20080026061A1 (en) * 2006-06-22 2008-01-31 Reichwein John F Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
CN102924412A (zh) * 2008-01-25 2013-02-13 先正达参股股份有限公司 用作杀虫剂的2-氰基苯基磺酰胺衍生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) * 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5378715A (en) * 1992-02-24 1995-01-03 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
NZ247440A (en) * 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
HUP9600663A2 (en) 1997-01-28
CN1061652C (zh) 2001-02-07
CO4700473A1 (es) 1998-12-29
DE59601122D1 (de) 1999-02-25
HU9600663D0 (en) 1996-05-28
FI960953A (fi) 1996-09-19
TW363060B (en) 1999-07-01
TR199600212A2 (tr) 1997-01-21
NO961072L (no) 1996-09-19
US5726194A (en) 1998-03-10
CZ80096A3 (en) 1996-10-16
CN1141919A (zh) 1997-02-05
CA2171934A1 (en) 1996-09-19
KR100424045B1 (ko) 2004-06-26
GR3029893T3 (en) 1999-07-30
ATE175666T1 (de) 1999-01-15
CZ288001B6 (cs) 2001-03-14
BR9601028A (pt) 1997-12-30
AR002284A1 (es) 1998-03-11
EP0733626B1 (de) 1999-01-13
SK280926B6 (sk) 2000-09-12
SK36396A3 (en) 1997-02-05
AU4803996A (en) 1996-09-26
DE19509950A1 (de) 1996-09-19
EP0733626A1 (de) 1996-09-25
DK0733626T3 (da) 1999-08-09
JPH08269027A (ja) 1996-10-15
PL184332B1 (pl) 2002-10-31
PL313280A1 (en) 1996-09-30
FI960953A0 (fi) 1996-02-29
KR960034189A (ko) 1996-10-22
CA2171934C (en) 2007-04-24
AU705559B2 (en) 1999-05-27
NO961072D0 (no) 1996-03-15
UA48116C2 (uk) 2002-08-15
ZA962144B (en) 1996-09-26
HUP9600663A3 (en) 1998-07-28
NO305907B1 (no) 1999-08-16
RU2168503C2 (ru) 2001-06-10

Similar Documents

Publication Publication Date Title
ES2128117T3 (es) Antagonistas del receptor de endotelina.
BR0007595A (pt) 4-(heterociclisulfonamido)-5-metóxi-6-(2-metoxifenó xi)-2-fenil-ou piridilpirimidinas como antagonistas de receptor de endotelina
ES2134870T3 (es) Antagonistas del receptor de adhesion.
CY1107617T1 (el) Σκευασμα που αποτελειται απο μεσυλικη (μεθανοσουλφονικη) φαιντολαμινη και η χρηση του
ES2191183T3 (es) Derivados 6,6- o 6,7-biciclicos que contienen pirido o pirimido sustituidos.
ES2090215T3 (es) Pigmentos silanizados y su empleo para inhibir el amarilleado de materiales sinteticos pigmentados.
AR036181A1 (es) Una composicion de limpieza para el lavado de ropa que comprende un agente de beneficio de polimero de injerto y al menos un ingrediente adicional de limpieza para el lavado de ropa y un metodo para administrar uno o mas beneficios para el lavado de ropa en la limpieza de una tela poniendo en contac
ATE416157T1 (de) Inhibitoren von integrin alpha-v-beta-6
PE20000127A1 (es) Derivado de bencenosulfonamida
Karaki et al. ETB receptor antagonist, IRL 1038, selectively inhibits the endothelin-induced endothelium-dependent vascular relaxation
ATE225349T1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
ES2113090T3 (es) Costura mediante pasador, con alta densidad de bucles.
GT200000197A (es) 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6- morfolin-4-il-4-o tolil-piridin-3-il)-isobutiramida.
DE69410081D1 (de) Zwischenprodukte für die Herstellung von Endothelinrezeptor-Antagonist-Triterpen-Derivaten
Eltze et al. Characterization of muscarinic receptorsmediating vasodilation in rat perfused kidney
ES2058716T3 (es) Maquina lavadora mejorada.
ES2166129T3 (es) Mezcla fungicida.
ES2132761T3 (es) Derivados del acido piperidin acetico utiles como antagonistas del fibrinogeno.
ES2043863T3 (es) Procedimiento para preparar derivados de la 1,2,5,6-tetrahidropiridina.
PE20040713A1 (es) Avermectina b1 y derivados de monosacaridos de avermectina b1 que tienen un sustituyente alcoximetilo en la posicion 4" o 4'
DK0684237T3 (da) Morpholinderivater
ES2189211T3 (es) Derivados de naftotiazolona activos en el receptor dopaminergico d 3.
MX9603045A (es) Antagonistas de los receptores endoteliales.
GT199500039A (es) Compuestos ariltios
DE69812010D1 (de) 4-Aminopyrrole (3,2-d) Pyrimidinen als Antagonisten des Neuropeptide Y Receptors

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 733626

Country of ref document: ES